Incidence of Antibodies Blocking Thyrotropin Effect<i>In Vitro</i>in Patients with Euthyroid or Hypothyroid Autoimmune Thyroiditis*

Chiovato, Luca; Vitti, Paolo; Santini, Ferruccio; López, Guadalupe; Mammoli, Claudia; Bassi, P; Giusti, Lia; Tonacchera, Massimo; Fenzi, Gianfranco; Pinchera, Aldo

doi:10.1210/jcem-71-1-40

Cited by 73 publications

(41 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…DELFIA free thyroxine (FT4) and DELFIA hTSH kits were purchased from Kabi Pharmacia (Wallac Oy, Turku, Finland). The interassay coefficients of variation were 11% (6-8 pmol/L), 7% (16)(17)(18)(19) pmol/L), and 8% (43-53 pmol/L) for the fT4 assay, and 6% (0.77-1.03 mU/L), 4% (4.3-5.7 mU/L), and 3% (22)(23)(24)(25)(26)(27)(28)(29)(30) (20,21). For as¬ says, the cells were subcultured onto 12-well plates and grown to confluence.…”

Section: Methodsmentioning

confidence: 95%

See 1 more Smart Citation

Specific Effects of Radioiodine Treatment on TSAb and TBAb Levels in Patients with Graves' Disease

Michelangeli

Poon²,

Topliss³

et al. 1995

Thyroid

View full text Add to dashboard Cite

Radioactive iodine (RAI)-induced changes in the levels of antibodies to the thyroid-stimulating hormone (TSH) re¬ ceptor (TRAb) in patients undergoing treatment for autoimmune thyroid disease have been well documented. Previous studies have reported effects on the overall level of the antibodies present, TSH-binding inhibitory im¬ munoglobulins (TBII), without detailed studies of specific effects on the levels of thyroid-stimulating (TSAb) or thy¬ roid-blocking antibodies (TBAb). More detailed studies have been reported only in individual cases. In this study, the values of TSAb, TBAb, and TBII were measured longitudinally in 33 patients (27 females and 6 males) who re¬ ceived RAI. The bioassays for TSAb and TBAb were performed in JP09 cells. Following RAI, there were signifi¬ cant and immediate effects on the values of TBII in 70% of patients. TBII levels fell in 7 patients (20%) (Group 1), rose in 16 patients (48%) (Group 2) or remained unchanged but elevated in 10 patients (32%) (Group 3). In the Group 1 patients, only TSAb were detectable and none of these patients became hypothyroid after treatment. In the 16 patients in Group 2, increases in TBII were attributable to specific increases in TSAb in 7 (44%), in TBAb in 3 (19%), and in both TSAb and TBAb in 3 (19%). There were 3 patients (19%) in this group in whom there was no detectable TSAb or TBAb activity despite the increase in TBII. Six patients from this group became hypothy¬ roid within 6 months of RAI treatment. In the 10 patients in Group 3, 5 patients (50%) were positive for TBAb only, 2 (20%) were TSAb-only positive, and 3 (30%) were both TSAb-and TBAb-positive. Five patients (50%) in this group became hypothyroid and all had TBAb present in their circulation. Our results show that there are di¬ verse changes in TBII, TSAb, and TBAb following RAI. Hypothyroidism occurred in 33% of the patients treated with RAI therapy and TBAb were present in 75% of these hypothyroid patients. When TBAb were present in the absence of TSAb, hypothyroidism occurred in 6 of 8 versus 3 of 14 where TSAb were present alone (p < 0.05). The development of hypothyroidism within 6 months of RAI treatment was not related to continuation or dosage of an¬ tithyroid drugs and was transient in 50% of patients. We conclude that early hypothyroidism following RAI ther¬ apy is associated with increased TBAb in some patients and that recognition of this clinical situation should avoid unnecessary life-long thyroxine replacement.

show abstract

Section: Methodsmentioning

confidence: 95%

“…Results were expressed as a percentage of inhibition (25) TBAb levels >25 were regarded as being positive. Both TSAb and TBAb levels were determined for all samples concurrently.…”

Section: Tsab and Tbab Assaysmentioning

confidence: 99%

Specific Effects of Radioiodine Treatment on TSAb and TBAb Levels in Patients with Graves' Disease

Michelangeli

Poon²,

Topliss³

et al. 1995

Thyroid

View full text Add to dashboard Cite

show abstract

“…On the other hand, it has been shown that over 20% of patients with goitrous Hashimoto's disease, who were initially in a hypothyroid state, may recover normal hormonal thyroid function under L-T4 therapy [15]. Furthermore, it has been re ported that this newborn thyroid function may persist for more than 1 year after L-T4 therapy is discontinued and seems to be related to a spontaneous decrease in serum TSH-blocking Ab levels [16][17][18][19], but not to thyroid status. In contrast, it has been recently shown in hypothyroid patients with goitrous Hashimoto's thyroiditis that both mean plasma TSH level and prevalence of serum TSH-R Ab decreased under L-T4 therapy and increased again after cessation of such a treatment.…”

Section: Discussionmentioning

confidence: 99%

“…Moreover, it has been demonstrated in these patients that the suppression of TSH secretion by thyroid hormone during antithyroid drug therapy in duced a more important decrease in plasma TSH-R Ab levels than that observed when antithyroid drug treat ment was given alone [13,14]. On the other hand, it has been demonstrated in patients with goitrous Hashimoto's thyroiditis that the hypothyroid state could be related to TSH-R Ab blocking the action of TSH at the gland level [16][17][18][19], Furthermore, it has been reported that patients with goitrous Hashimoto's thyroidits in an initially hypo thyroid state may recover a normal thyroid function dur ing L-T4 therapy [ 15]. This newborn normal thyroid func tion seems to be related to a spontaneous decrease in TSH-R Ab [ 16].…”

mentioning

confidence: 99%

Effects of Thyroid Status on Thyroid Autoimmunity Expression in Surgically Induced Hypothyroid Patients with Graves’ Disease

Rieu

Richard²,

Sadoudi³

et al. 1995

Horm Res

View full text Add to dashboard Cite

We investigated, in 20 patients with Graves’ disease and presenting with both a surgically induced hypothyroid state and increased serum antibodies (Ab) to the TSH receptor (R) levels, the relationships between thyroid status and the serum TSH-R or peroxidase (TPO) Ab levels under L-T₄ treatment and after L-T₄ cessation. The prevalence of positive TSH-R Ab (100%) and the log mean TSH-R Ab level (1.41 ± 0.04%) observed during the surgically induced hypothyroid state decreased (p < 0.001, p < 0.01, respectively) under L-T₄ therapy (prevalence of positive TSH-R Ab = 50%, log mean TSH-R Ab level =1.21 ± 0.05%) and increased again (p < 0.001) after L-T₄ cessation (prevalence of positive TSH-R Ab = 85%, log mean TSH-R Ab level = 1.45 ± 0.06%) to reach levels lower ( < 0.01) than that observed during the hypothyroid state for prevalence of positive TSH-R Ab but similar to that obtained during such a state for log mean TSH-R Ab value. The log mean TPO Ab level obtained during the surgically induced hypothyroid state (3.2 ± 0.5 titer) decreased (p < 0.02) under L-T₄ therapy (1.8 ± 0.2 titer) and increased again (p < 0.02) after L-T₄cessation (3.0 ± 0.5 titer) to reach a similar level to that obtained during the surgically induced hypothyroid state. There were positive correlations between log TSH levels and log TSH-R Ab values (r = 0.40, p < 0.001) or log TPO Ab levels (r = 0.33, p < 0.01). Likewise, negative correlations (p < 0.01) were found between FT₄ values and log TSH-R Ab levels (r = -0.34) or log TPO Ab values (r = -0.31). In conclusion, our results suggest that thyroid hormonal status can modulate thyroid autoimmunity expression, such as serum TSH-R and TPO Ab levels in hypothyroid patients with Graves’ disease.

show abstract

“…TSAb, after the interaction with the receptor, increase cAMP accumulation causing goiter and hyperthyroidism (2,3). In atrophic thyroiditis (AT), thyroid-stimulating blocking antibodies (TSHBAb) are TSH antagonists, inhibiting TSH binding or TSH-increased cAMP levels causing thyroid atrophy and hypothyroidism (2,(4)(5)(6). The different activities of TSAb and TSHBAb suggest they might interact with different epitopes on the TSHr (2).…”

Section: Introductionmentioning

confidence: 99%

TSH receptor antibodies do not alter the function of gonadotropin receptors stably expressed in eukaryotic cells

Tonacchera

Ferrarini

Dimida

et al. 2004

European Journal of Endocrinology

View full text Add to dashboard Cite

Objective: TSH receptor (TSHr) mediates the activating action of TSH on the thyroid gland resulting in the growth and proliferation of thyrocytes and thyroid hormone production. TSHr is a major autoantigen in Graves' disease (GD) and is the target for TSHr antibodies. In GD, thyroid-stimulating antibodies (TSAb) are competitive agonists of TSH. In atrophic thyroiditis (AT), thyroid-stimulating blocking antibodies (TSHBAb) are TSH antagonists. The TSHr together with the LH receptor (LHr) and FSH receptor (FSHr) are G-protein-coupled receptors with considerable amino acid homologies in the extracellular domain. We studied the cross-reactivity of the antibodies measured in sera from patients with GD or AT on the LHr and FSHr function. Methods: We tested the activity of TSAb and TSHBAb in cell lines expressing the LHr and the FSHr. To this purpose a pSVL-FSHr construct was transfected in CHO cells and one clone was used. Results: Twenty-eight sera from patients with GD and four from patients with AT, known to contain TSHr antibodies measured with a radioreceptor assay, were selected. TSAb and TSHBAb activities were measured in CHO cells expressing the TSHr (CHO-TSHr). TSAb and TSHBAb were then tested with the cell lines expressing the LHr and the FSHr for their ability to elicit cAMP accumulation or inhibit FSH/LH-induced cAMP production. None of the TSAb identified was able to stimulate cAMP increase in CHO-LHr or CHO-FSHr. Similarly, none of the TSHBAb was able to block the cAMP response induced by FSH or LH in the respective cell lines. Conclusions: Our results confirm the notion of the organ-specific nature of the TSHr antibodies.

show abstract

Incidence of Antibodies Blocking Thyrotropin EffectIn Vitroin Patients with Euthyroid or Hypothyroid Autoimmune Thyroiditis*

Cited by 73 publications

References 26 publications

Specific Effects of Radioiodine Treatment on TSAb and TBAb Levels in Patients with Graves' Disease

Specific Effects of Radioiodine Treatment on TSAb and TBAb Levels in Patients with Graves' Disease

Effects of Thyroid Status on Thyroid Autoimmunity Expression in Surgically Induced Hypothyroid Patients with Graves’ Disease

TSH receptor antibodies do not alter the function of gonadotropin receptors stably expressed in eukaryotic cells

Contact Info

Product

Resources

About

Incidence of Antibodies Blocking Thyrotropin EffectIn Vitroin Patients with Euthyroid or Hypothyroid Autoimmune Thyroiditis*

Cited by 73 publications

References 26 publications

Specific Effects of Radioiodine Treatment on TSAb and TBAb Levels in Patients with Graves' Disease

Specific Effects of Radioiodine Treatment on TSAb and TBAb Levels in Patients with Graves' Disease

Effects of Thyroid Status on Thyroid Autoimmunity Expression in Surgically Induced Hypothyroid Patients with Graves&rsquo; Disease

TSH receptor antibodies do not alter the function of gonadotropin receptors stably expressed in eukaryotic cells

Contact Info

Product

Resources

About

Effects of Thyroid Status on Thyroid Autoimmunity Expression in Surgically Induced Hypothyroid Patients with Graves’ Disease